Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)
- Koncept Analytics
- March 2018
- 68 pages
Lysosomal Storage Disease (LSD) is a genetic disorder that causes various types of nervous system disorders such as clinical abnormalities and cellular dysfunction. There are more than 65 categories of LSD. This disease can be classified into Lipid Metabolism Disorder and Glycoprotein Metabolism Disorder. Further Lipid Metabolism Disorder is categorized into Gaucher disease & Fabry disease and Glycoprotein Metabolism Disorder into Pompe disease. LSD develops mainly due to deficiency of lysosomal enzyme in the living body. A person suffering from LSD could experience problems like abnormal growth of bones, delay movement of body, deafness, blindness, dementia, respiratory problems, fatigue/weakness, bone & joint deformity, organ enlargement, lung dysfunction, severe & fatal physical & mental health deterioration.
The global LSD market is expected to grow with growing Ashkenazi (Eastern and Western Europe) population, increasing pharmaceutical R&D spending, growing disposable income, rising healthcare expenditure and accelerating economic growth. Key trends of this rare disease market includes progressing drugs under pipeline and increasing preference towards gene therapy. However, there are some factors which can hinder growth of the market including stringent regulations and limited access to patent rights.
The report “Global Lysosomal Storage Disease (LSD) Market (Fabry, Gaucher & Pompe): Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook.
The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the global market. The report profiles the key players of the market including Pfizer Inc., Sanofi S.A., Shire Plc and Protalix BioTherapeutics, Inc.
Have query on this report?Make an Enquiry
Table of Content
1. Market Overview
1.1 Lysosomal Storage Disease (LSD)
1.2 Classification of LSD
1.6 Upcoming Treatment
2. 2. Global LSD Market Analysis
2.1 Global LSD Market Forecast by Value
2.2 Global LSD Market Value by Category
2.3 Global Fabry Disease Market Forecast by Value
2.4 Global Fabry Disease Market Value by Drugs
2.4.1 Global Fabrazyme Sales Value
2.4.2 Global Replagal Sales Value
2.4.3 Global Galafold Sales Value
2.5 Global Gaucher Disease Market Forecast by Value
2.6 Global Gaucher Disease Market Value by Drugs
2.6.1 Global Cerezyme Sales Value
2.6.2 Global Vipriv Sales Value
2.6.3 Global Cerdelga Sales Value
2.7 Global Pompe Disease Market Forecast by Value
2.8 Global Pompe Disease Market Value by Drugs
2.8.1 Global Myozyme Sales Value
3. Market Dynamics
3.1 Growth Drivers
3.1.1 Growing Ashkenazi (Eastern and Western Europe) Population
3.1.2 Rising Pharmaceutical R&D Spending
3.1.3 Increasing Disposable Income
3.1.4 Growing Healthcare Expenditure
3.1.5 Accelerating Economic Growth
3.2 Key Trends & Developments
3.2.1 Progressing Drugs under Pipeline
3.2.2 Increasing Preference towards Gene Therapy
3.3.1 Stringent Regulations
3.3.2 Limited Access to Patent Rights
4. Competitive Landscape
4.1 Global Market
4.1.1 Revenue Comparison of Key Players
4.1.2 Market Cap Comparison of Key Players
4.1.3 Global LSD Market-Annual Treatment Cost Comparison by Company
Drugs under Development for Lysosomal Storage Disease (2017)
Global LSD Market Key Players - Revenue Comparison (2017)
Global LSD Market-Annual Treatment Cost Comparison by Company (2017)
Pfizer Inc. Significant Agreements (2017/2018)
Sanofi S.A. Significant Acquisitions (2017/2018)
Protalix BioTherapeutics, Inc. Product Pipeline (2017)
The team was the biggest help to us. Not only were we provided with customized solutions but also we were guided through the most complicated situations. The information was on-point yet comprehensive. The experience was absolutely satisfying and helped us turn many challenges into opportunities.
Ours is a startup with a unique set of challenges and we were therefore hesitant but the team totally put us at ease with their knowledge and expertise. Our business and its challenges were understood perfectly and help was extended accordingly. The tailor made approach really helped us gain the most informative insights.
The report repository is absolutely impressive –updated and exhaustive in terms of markets covered and information provides. Besides, with the support extended to us by the team, we could reduce costs as well as move to sustainable growth. This really helped us tap into new opportunities. Happy to have gone ahead with ResearchMos.us.
We have had a long term engagement with ResearchMoz.us and never have we felt that the work done and help extended were below flawless. The report repository is one of the best one can hope to tap into. Recently, our partner businesses opted for consultancy services and they are all thrilled with the outcome.
Insights from reports helped us improve our profit margins significantly. Most of the knowledge we needed on the market were provided to us on a granular basis. From trends, and drivers to competitive analysis, the information was not just crisp but also insightful. That helped us chart a robust growth strategy and as of now we are happy to state that we are reaping big benefits.
More from Pharmaceutical
PharmaceuticalChinese Markets for Mental Illness Drugs
PharmaceuticalChinese Markets for Anti-Dermatomycosis Skin Drugs
PharmaceuticalChinese Markets for Incretion Drugs
PharmaceuticalChinese Markets for Hypertension Drugs
Pharmaceuticals and HealthcareGlobal Bionic Ears Market Professional Survey Report 2017
Pharmaceuticals and HealthcareNeuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017
Pharmaceuticals and HealthcareHepatitis Drug Development Pipeline Review, 2017